4-(1-oxohexadecyl)morpholine | 5299-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(1-oxohexadecyl)morpholine
• 英文别名: NSC 3149；1-morpholinohexadecan-1-one；N-palmitoyl-morpholine；4-hexadecanoyl-morpholine；4-palmitoyl-morpholine；4-Palmitoyl-morpholin；1-(Morpholin-4-yl)hexadecan-1-one；1-morpholin-4-ylhexadecan-1-one
• CAS: 5299-68-3
• 化学式: C₂₀H₃₉NO₂
• 分子量: 325.535
• InChiKey: CSXWLOVEZJWZMB-UHFFFAOYSA-N

物化性质

• 熔点：
  38-39 °C(Solv: chloroform (67-66-3); methanol (67-56-1))
• 沸点：
  453.6±38.0 °C(Predicted)
• 密度：
  0.927±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1-oxohexadecyl)morpholine 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 四氢呋喃 为溶剂， 生成 4-十六烷基-吗啉
  参考文献：
  名称：

  长烷基链酰胺，胺及其衍生物对犬round虫幼虫的杀线虫活性。

  摘要：

  检查了具有长烷基链的酰胺和胺对犬round虫第二阶段幼虫的杀线虫活性。在氮上具有较小取代基的长链酰基酰胺显示出更强的活性，环状胺酰胺的活性强于无环酰胺。在一系列同源酰胺中，活性取决于烷基链长：在最佳链长处达到最大值，而在较短和较长的同系物中均降低。通过使用双线性模型分析了同系物的活性与疏水性之间的关系。对于所有中性酰胺，提供最大活性的化合物的疏水性均相似，但分子中具有额外胺基的酰胺具有不同的值。具有长烷基链的叔胺及其盐也具有与相应酰胺相当的杀线虫活性。这些盐以低于其临界胶束浓度的浓度杀死幼虫，表明它们表现为杀线虫作用的单个分子。

  DOI：

  10.1248/cpb.40.3234
• 作为产物：
  描述：

  棕榈酸 在 硫酸 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 4-(1-oxohexadecyl)morpholine
  参考文献：
  名称：

  Antiproliferative activity of synthetic fatty acid amides from renewable resources

  摘要：

  In the work, the in vitro antiproliferative activity of a series of synthetic fatty acid amides were investigated in seven cancer cell lines. The study revealed that most of the compounds showed antiproliferative activity against tested tumor cell lines, mainly on human glioma cells (U251) and human ovarian cancer cells with a multiple drug-resistant phenotype (NCI-ADR/RES). In addition, the fatty methyl benzylamide derived from ricinoleic acid (with the fatty acid obtained from castor oil, a renewable resource) showed a high selectivity with potent growth inhibition and cell death for the glioma cell line-the most aggressive CNS cancer. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.019

文献信息

• Therapeutic use of mono and bicarboxylic acid amides active at the
  申请人：Lifegroup S.p.A.

  公开号：US05990170A1

  公开（公告）日：1999-11-23

  The following description concerns a therapeutic method for the treatment of diseases connected with the modulation of the cannabinoid peripheral receptor, comprising administering amidic derivatives of mono and bicarboxylic acids with aminoalcohols or arninoethers selectively active on said receptor.

  以下描述涉及一种治疗与大麻素外周受体调节相关疾病的治疗方法，包括通过给予对该受体具有选择性活性的氨基醇或氨基醚的单和双羧酸酰胺衍生物进行治疗。
• 2-oxothiazole compounds and method of using same for chronic inflammatory disorders
  申请人：Kokotos George

  公开号：US09597318B2

  公开（公告）日：2017-03-21

  The invention provides compounds of formula (I) wherein X is O or S; R1 is H, OH, SH, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, halo, haloC1-6alkyl, CN, C1-6-alkyl, OC1-6alkyl, C1-6alkylCOOH, C1-6alkylCOOC1-6alkyl, C2-6-alkenyl, C3-10cycloalkyl, C6-10aryl, C1-6alkylC6-10aryl, heterocyclyl, heteroaryl, CONH2, CONHC1-6alkyl, CON(C1-6alkyl)2, OCOC1-6alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R2 is as defined for R1 or R1 and R2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R5; R3 is H, halo (preferably fluoro), or CHal3 (preferably CF3); each R5 is defined as for R1; V1 is a covalent bond, —O—, or a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; M1 is absent or is a C5-10 cyclic group or a C5-15 aromatic group; and R4 is H, halo, OH, CN, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, haloC1-6alkyl, a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group, said C1-20alkyl or C2-20alkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; with the proviso that the group V1M1R4 as a whole provides at least 4 backbone atoms from the C(R3) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.

  该发明提供了以下式（I）的化合物，其中X为O或S；R1为H、OH、SH、硝基、NH2、NHC1-6烷基、N（C1-6烷基）2、卤素、卤代C1-6烷基、CN、C1-6烷基、OC1-6烷基、C1-6烷基COOH、C1-6烷基COOC1-6烷基、C2-6烯基、C3-10环烷基、C6-10芳基、C1-6烷基C6-10芳基、杂环烷基、杂芳基、CONH2、CONHC1-6烷基、CON（C1-6烷基）2、OCOC1-6烷基，或者是酸性基团，例如包含羧基、磷酸基、磷酸酯基、硫酸基、磺酸基或四唑基团的基团；R2如R1定义或R1和R2一起形成一个6-成员芳香环，可选地由多达4个R5基团取代；R3为H、卤素（优选氟素），或CHal3（优选CF3）；每个R5如R1定义；V1为共价键，—O—，或C1-20烷基，或C2-20单烯或多不饱和烯基；所述烷基或烯基基团可选地由O、NH、N（C1-6烷基）、S、SO或SO2中选择的一个或多个杂原子中断；M1不存在或为C5-10环烷基或C5-15芳基；R4为H、卤素、OH、CN、硝基、NH2、NHC1-6烷基、N（C1-6烷基）2、卤代C1-6烷基、C1-20烷基，或C2-20单烯或多不饱和烯基，所述C1-20烷基或C2-20烯基基团可选地由O、NH、N（C1-6烷基）、S、SO或SO2中选择的一个或多个杂原子中断；但条件是，V1M1R4作为一个整体至少提供来自C（R3）基团的4个骨架原子；或其盐、酯、溶剂化合物、N-氧化物或前药；用于治疗慢性炎症症状。
• A Convenient Protocol for the Synthesis of Fatty Acid Amides
  作者：Jens Nolsøe、Silje Johansson、Tonje Johannessen、Christiane Ellefsen、Mali Ristun、Simen Antonsen、Trond Hansen、Yngve Stenstrøm

  DOI：10.1055/s-0037-1611939

  日期：2019.1

  Several classes of biologically occurring fatty acid amides have been reported from mammalian and plant sources. Many amides conjugated with fatty acids of mammalian origin exhibit specific activation of individual receptors. Their potential as pharmacological tools or as lead compounds towards the development of novel therapeutics is of great interest. Hence, access to such amides by a practical,

  已经从哺乳动物和植物来源报道了几类生物存在的脂肪酸酰胺。许多与哺乳动物来源的脂肪酸结合的酰胺表现出对个体受体的特异性激活。它们作为药理学工具或作为开发新疗法的先导化合物的潜力引起了人们极大的兴趣。因此，需要在不影响敏感功能的几何形状或位置的情况下，通过实用、高产和可扩展的协议来获取此类酰胺。满足所有这些要求的方案包括用羰基二咪唑 (CDI) 活化相应的酸，然后与所需的胺或其盐酸盐反应。已经以通常高产率制备了五十多种化合物。
• A Photochemical Protocol for the Synthesis of Weinreb and Morpholine Amides from Carboxylic Acids
  作者：Asimina Bourboula、Olga G. Mountanea、George Krasakis、Christiana Mantzourani、Maroula G. Kokotou、Christoforos G. Kokotos、George Kokotos

  DOI：10.1002/ejoc.202300008

  日期：——

  A photochemical protocol for the synthesis of Weinreb amides and morpholine amides from carboxylic acids is presented. Various carboxylic acids were directly coupled to N,O-dimethylhydroxylamine and morpholine, upon irradiation with either LED 370 nm or sunlight in the presence of 4-dimethylaminopyridine and bromotrichloromethane, providing amides in moderate to high yields.

  提出了从羧酸合成 Weinreb 酰胺和吗啉酰胺的光化学方案。在 4-二甲基氨基吡啶和溴三氯甲烷存在下，用 370 nm 的 LED 或阳光照射，各种羧酸直接与N , O-二甲基羟胺和吗啉偶联，以中等到高产率提供酰胺。
• Penetration enhancers for transdermal delivery of systemic agents
  申请人：RESEARCH TRIANGLE PHARMACEUTICALS LTD.

  公开号：EP0268222A2

  公开（公告）日：1988-05-25

  This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer having the structural formula wherein X may represent sulfur, oxygen or nitrogen; a and b may be 0 or 1, c may be 0, 1 or 2, except that when X is oxygen, a, b and c are 0, when X is nitrogen c is 0 and only one of a or b is 1, and when X is sulfur a and b are0; A is a branched or a straight chain, divalent aliphatic radical having from 0 to 2 double bonds; Rʹ is selected from the group consisting of H, a lower alkyl group having from 1 to 4 carbon atoms, phenyl, lower alkyl or halogen substituted phenyl, acetamido, halogen, piperidinyl, lower alkyl or halogen substituted piperidinyl, carbalkoxy, carboxamide, and alkanoyl; and R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms, wherein Rʺ is H or halogen, and salts, e.g. acid or quaternary derivatives, thereof. These compositions are useful in topical or transdermal applications of the physiologically-active agent.

  本发明涉及一种在透皮装置或制剂中通过人和动物的皮肤或粘膜施用全身活性剂（包括治疗剂）的方法，包括与所述全身活性剂一起局部施用有效量的膜渗透促进剂，其结构式为 其中 X 可以代表硫、氧或氮；a 和 b 可以是 0 或 1，c 可以是 0、1 或 2，但当 X 是氧时，a、b 和 c 是 0，当 X 是氮时，c 是 0，a 或 b 中只有一个是 1，当 X 是硫时，a 和 b 是 0；A 是具有 0 至 2 个双键的支链或直链二价脂族基；Rʹ 选自由 H、具有 1 至 4 个碳原子的低级烷基、苯基、低级烷基或卤素取代的苯基、乙酰氨基、卤素、哌啶基、低级烷基或卤素取代的哌啶基、碳烷氧基、羧酰胺和烷酰基组成的组；以及 R 是氢或具有 1 至 4 个碳原子的低级烷基、 其中 Rʺ 是氢或卤素，以及它们的盐，如酸或季衍生物。这些组合物可用于生理活性剂的局部或透皮应用。